761423-87-4

• 常用中文名：伊格列净
• 常用英文名：Ipragliflozin
• CAS号：761423-87-4
• 分子式：C₂₁H₂₁FO₅S
• 分子量：404.452
• 相关类别： 信号通路 跨膜转运 SGLT
• 发布时间：2018-02-14 08:00:00
• 更新时间：2025-08-20 09:49:03
• Ipragliflozin (ASP1941)是高活性SGLT2选择性抑制剂,IC50为2.8 nM,对SGLT1/3/4/5/6几乎无活性。

名称

• 中文名: 伊格列净
• 英文名: (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 英文别名: D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-; ASP1941; UNII-3N2N8OOR7X; ASP 1941; (1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol; Suglat; Ipragliflozin

物化性质

• 密度: 1.5±0.1 g/cm3
• 沸点: 628.8±55.0 °C at 760 mmHg
• 分子式: C₂₁H₂₁FO₅S
• 分子量: 404.452
• 闪点: 334.1±31.5 °C
• 精确质量: 404.109375
• PSA: 118.39000
• LogP: 5.59
• 外观性状: 粉末
• 蒸汽压: 0.0±1.9 mmHg at 25°C
• 折射率: 1.684
• 储存条件: -20℃

生物活性

• 描述: Ipragliflozin (ASP1941)是高活性SGLT2选择性抑制剂,IC50为2.8 nM,对SGLT1/3/4/5/6几乎无活性。
• 相关类别:
  信号通路 >> 跨膜转运 >> SGLT
  研究领域 >> 代谢疾病
• 参考文献:

  [1]. Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20(10):3263-79.

  [2]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.

  [3]. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36.

  [4]. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44.

  [5]. Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55.

  [6]. Yoshikawa T, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res. 2017 Jul;40(7):646-651.

  [7]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.

合成路线

761423-01-2 ~88% 761423-87-4

文献：Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 13 ;

1034305-21-9 ~97% 761423-87-4

文献：Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 15 ;

1034305-11-7 ~% 761423-87-4

文献：Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

1034305-17-3 ~% 761423-87-4

文献：Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

93777-26-5 ~% 761423-87-4

文献：Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

95-15-8 ~% 761423-87-4

文献：Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

上下游产品

上游产品  5
1034305-21-9 1034305-11-7 1034305-17-3 93777-26-5
95-15-8
下游产品  0